Skip to main content

Three RNAi-Related Patent Applications Published By US Patent Office

Premium

Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid. Number: 20050032733. Filed: April 16, 2004. Lead Inventor: James McSwiggen, Sirna Therapeutics.

The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short-interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules capable of mediating RNA interference against target nucleic acid sequences.

“The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism,” the abstract adds.


Title: Oligomeric Compounds Having Modified Bases for Binding to Adenine and Guanine and Their Use in Gene Modulation. Number: 20050032069. Filed: Aug. 6, 2003. Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals.

According to its abstract, the patent application covers “oligomer compositions comprising first and second oligomers … wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer; at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid; and at least one of the first or second oligomers has a modified base for binding to an adenine or guanine base in the opposite strand.”

The abstract adds that “oligonucleotide/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex, wherein the oligomer has a modified base for binding to an adenine or guanine base in the opposite strand.”


Title: Sugar and Backbone-Surrogate-Containing Oligomeric Compounds and Compositions for Use in Gene Modulation. Number: 20050032068. Filed: Aug. 5, 2003. Lead Inventor: Thazha Prakash, Isis Pharmaceuticals (Alnylam Pharmaceuticals).

The patent application, its abstract states, covers “compositions comprising first and second oligomers … wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer; at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid; and at least one of the first or second oligomers includes a modified sugar and/or backbone modification.

“In some embodiments the modification is a peptide nucleic acid, a peptide nucleic acid mimic, a morpholino nucleic acid, hexose sugar with amide linkage, cyclohexenyl nucleic acid, or an acyclic backbone moiety,” the abstract states. “Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex, wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.”

 

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.